In Q2 2025, Stoke Therapeutics achieved significant revenue growth from collaboration agreements, reducing its net loss compared to the prior year. Increased R&D and G&A expenses reflect advancing clinical programs, including the Phase 3 EMPEROR study for zorevunersen. The company ended the quarter with a strong cash position, projecting runway into mid-2028.

Stoke Therapeutics reported a net income of $112.9 million for the first quarter of 2025, a significant increase from a net loss in the prior year, driven by substantial revenue from a collaboration agreement with Biogen. The company also reported strong cash reserves, anticipated to fund operations beyond 2H 2027.

In Q4 2024, Stoke Therapeutics reported $22.6 million in revenue from license and collaboration agreements. The company incurred a net loss of $10.5 million and continued investing heavily in R&D and administrative functions. With $246.7 million in cash and marketable securities, the company has a solid cash runway extending to mid-2028.

Stoke Therapeutics reported revenue of $4.9 million and a net loss of $26.4 million for the third quarter of 2024. The company had $269.2 million in cash, cash equivalents, and marketable securities as of September 30, 2024.

Stoke Therapeutics reported revenue of $4.8 million and a net loss of $25.7 million for the second quarter of 2024. The FDA removed the Partial Clinical Hold as the company advances toward a Phase 3 registrational study of zorevunersen.

Stoke Therapeutics reported a net loss of $26.4 million, or $0.57 per share, for the first quarter of 2024. The company's cash and cash equivalents totaled $178.6 million as of March 31, 2024. Revenue for the quarter was $4.2 million, primarily from the Acadia Pharmaceuticals collaboration.

Stoke Therapeutics reported a revenue of $2.8 million and a net loss of $27.0 million for the fourth quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled $201.4 million as of December 31, 2023, anticipated to fund operations to the end of 2025.